Open Peer Review on Qeios

[Review] Sarcopenia in Coronavirus Disease (COVID-19): All to Know from Basic to Nutritional Interventions from Hospital to Home

Mohammed Reza Shadmand Foumani Moghadam[1], Sajedeh Jandari[2], Amirmohammad Vaezi[3], Reza Rezvani[2]

1 Varastegan Institute for Medical Sciences
2 Mashhad University of Medical Sciences
3 Khavaran Higher Education Institute

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.

Abstract

Coronavirus Disease (COVID-19) became a worldwide pandemic with a high hospitalisation rate in March 2020. COVID-19 infection and sarcopenia concentrate on a same pathway that higher the risk of sarcopenia. The resulted sarcopenia can cause severity of the disease, lower the treatment efficiency and physical disabilities for surviving COVID-19 patients. This review provides a practical overview of the importance, metabolism, mechanism, and link of COVID-19 with Sarcopenia. In addition, all the concerns and treatments that healthcare expertise required to consider from the hospital to patients home with their timeline are explained. Nevertheless, sarcopenia is not limited to the hospital and can continue developing long after the COVID-19 recovery. This situation makes continuous follow-up, sarcopenia monitoring, and interventions necessary until the removal of risks even after recovery. Otherwise, a higher prevalence of sarcopenia and, as a result, higher morbidity, mortality, dependency, and disabilities in survived COVID-19 patients can be expected.

Mohammad Reza Shadmand Foumani Moghadam[1], **Sajedeh Jandari**[2], **Amirmohammad Vaezi**[3], **Reza Rezvani**[2*]

[1] *Department of Nutrition Sciences (Med-Sci), Varastegan Institute for Medical Sciences, Mashhad, Iran*

[2] *Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

[3] *Department of Biology, Kavian Higher Education Institute, Mashhad, Iran*

[*]**Corresponding author:**

Reza Rezvani MD. PhD. PDF.

Assistant Professor of clinical nutrition

Head of the Research Committee of the Nutrition Department

School of Medicine, Mashhad University of Medical Sciences.

Azadi Square, Campus of University, Mashhad, Iran

Postal Code: 9177948564

Telephone: +98-5138002418

Email addresses: RezvaniR@mums.ac.ir; Reza.Rezvani.1@ulaval.ca; Reza.Rezvani.rr@gmail.com.

Short title: Sarcopenia and COVID-19.

Keywords: Sarcopenia, COVID-19, SARS-CoV-2, Mechanism, Nutrition.

Highlights

- The mechanism of sarcopenia can be so close to COVID-19 pathology that requires special care.
- Sarcopenia in COVID-19 patients is not limited to the hospital and can develop after recovery through the muscle-fat interaction cycle.
- COVID-19 Sarcopenia can become the leading cause of disabilities, morbidity, and mortality in the future.
- SARC-F, PG-SGA, MNA tools, and EWGSOP sarcopenia criteria can be proper tools for sarcopenia assessment during hospitalisation.
- Nutrition therapy can be the key intervention in stopping sarcopenia.
- Some interventions are better to be continued for months after the discharge.

Introduction

The 2019 novel coronavirus disease (COVID-19) became a worldwide pandemic on March 11, 2020, as the report of the World Health Organization (WHO) [1]. As the reports, more than 508 million cases and about 6.21 million deaths were caused by this disease until May 2022. Although standard diagnostic and prevention methods for COVID-19 have been established, a suitable effective treatment method is still lacking [2]. While most researchers have tried to solve the pandemic by studying medications and developing vaccines, the destructive effect of most co-diseases is not considered [2].

One of these diseases is "sarcopenia", defined as a decrease in muscle strength, mass, or performance[3]. Sarcopenia in the 1980s was defined as a progressive and generalised skeletal muscle disorder and has been classified as a disease since 2016 by World Health Organization (WHO) [3][4]. Sarcopenia can lead to more mortality risk during hospitalisation or disabilities, falling, and functional limitations after discharge [3][4]. The leading cause of sarcopenia is ageing (usually more than 65 years old) or facing any catabolic situation. However, the lifestyle, nutritional pattern, social-economic status, and physical activity are other risk factors [4][5].

By considering the destructive effects of sarcopenia in hospitalisation and changes in the lifestyle of COVID-19 patients after hospitalisation, controlling this disease in COVID-19 patients is necessary. This review aims to review Sarcopenia in

COVID-19 from basic to clinical science and provide considerations to treatment within the hospital and beyond.

Importance and the triangle link of Sarcopenia, COVID-19 and outcome

Sarcopenia is one of the most common hospitalisation outcomes among all hospitalised patients[6][7]. The previous studies that assessed the effect of sarcopenia on the survival of patients with cancer [8], hepatocellular carcinoma [9], cardiovascular [10], and critical illness [6][7] also showed the importance of this disease. A higher length of stay, more inflammatory response, lower response to treatment, severe clinical status, and higher morbidity and mortality are sarcopenia's main impacts on hospitalised patients [11]. There is also evidence that sarcopenia impacts mechanical ventilation efficiency, which is essential during COVID-19 hospitalisation [6][7]. All these effects are independent of the effect of the main illness that shows its impact.

At the same time, COVID-19 hospitalisation, in many cases, is considered a critical illness[2][12][13]. Despite strong evidence specifying that critical illness caused by COVID-19 is qualitatively different from other diseases making its treatment harder, this situation can still elevate the process of sarcopenia [6][7][13]. In fact, these differences are in patterns of symptoms and responses to treatment that make COVID-19 unpredictable [13]. For example, a trend indicates that treatment with corticosteroids is harmful in mild COVID-19 patients, whereas there is a substantial benefit among patients with critical respiratory failure [13]. A high inflammatory and metabolic response caused by COVID-19 also impacts treatment and sarcopenia [12][13][14]. While having any non-communicable diseases (NCDs) is the other factor that can increase the risk of mortality in COVID-19 patients [3][4][12][13][14][15]. All these conditions show the complexity of COVID-19 treatment, which can get more difficult with sarcopenia.

Things get harder when we consider the fact that sarcopenia is not just a passive disease. Sarcopenia has long-term effects that can cause obstinate functional disability one year after discharge [7]. There is also a significantly increased risk for readmission in older adults hospitalised with sarcopenia than in people without sarcopenia [16]. The concern grows when despite knowing the importance of preventing sarcopenia, it is still not a significant concern in COVID-19 patients.

The danger of mortality and morbidity can remain even after hospitalisation. Sarcopenia is a complex multifactorial disease that is not limited to the hospital [3][4][5]. One of the harmful effects of sarcopenia with long-term self-effect is the muscle-fat interaction cycle [17] (Figure 1). In this cycle that repeats and self-increases the sarcopenia severity, energy expenditure decreases the muscle mass while the dietary intake may stay the same. This condition leads to a positive energy balance in the body for fat mass growth. This obesity-sarcopenia leads to inflammation, insulin resistance, morbidity, and functional limitations in people who fully recovered from COVID-19 [3][4][5][17].

While concerns like having an inactive lifestyle and a poor diet can enhance the speed of sarcopenia during quarantine and after discharge [18][19][20], the close mechanism of Sarcopenia and COVID-19 is discussed in the following is another concern that must be considered. For this reason, it is crucial to control this unpleasant disease, especially in COVID-19 patients, as much as other risk factors of COVID-19 patients' mortality.

The mechanism between COVID-19 and Sarcopenia

Despite the mechanism of Sarcopenia and COVID-19 following different pathways at the first contact, their impact on each other can be significant. By deep exploring, many pathways in both COVID-19 and Sarcopenia follow the same patterns with the same triggers (Figure 2). However, establishing a firm pathway to link COVID-19 and Sarcopenia still requires more investigations. For understanding the pathways, recognising the mechanism of each disease is essential.



Figure 2. The mechanism of developing Sarcopenia during COVID-19 infection could lead to the elevated risk of sarcopenia within patients that could lead to a higher risk of mortality, especially during hospitalisation. Blues main factors; grey: outcomes of sarcopenia; white: factors that generally are an outcome of other factors that have effect sarcopenia

Mechanism of COVID-19

The mechanism of COVID-19 is still unclear, but one of the primary outcomes of its infection is the inflammatory response that can drive into inflammatory cytokine storms in a short time from the infection [14][21]. One of the first results of increasing SARS-CoV-2 infections is IL-1β which elevates immediately after infection [14][22]. This condition at following releases pathogen-associated molecular patterns (PAMPs), such as viral RNA, and damage-associated molecular patterns (DAMPs), including ATP, DNA, and ASC oligomers [22]. As follow, a wave of local inflammation ensues, involving increased secretion of the pro-inflammatory cytokines and chemokines like IL-6, IFNγ, MCP1, and IP-10 released into the blood of afflicted patients [22]. IFNγ, TNF, and IL-2 are also increased in the next phase of defense, which leads to more inflammation in these patients [14][22].

In addition to inflammatory response, COVID-19 infection is associated with hormone changes[23]. The considerable

changes in hormones are in sex hormones, including testosterone, estrogen, and progesterone [23]. An increase in insulin-resistant and estrogen during critical illness also resulted as well as a decrease in Testosterone, Insulin-like growth factor 1 (IGF-I), and human growth hormones (HGH) in COVID-19 hospitalisation patients [23][24][25]. Myostatin, an important hormone in muscle metabolism, is another hormone that effectively increases during hospitalisation to inhibit muscle cell growth for saving energy and amino acids for metabolic pathways [26][27]. All these hormones changes have a trend in lowering the muscle mass [23][24][25][26][27].

Malnutrition is another concern during COVID-19 infection that can be resulted even in acute COVID-19 patients[28]. According to reports, the most eating complications in COVID-19 patients were loss of appetite (anorexia), sore mouth (xerostomia), changes in taste, and nausea [28][29]. These eating complications can be ranged from mild to severe, but in nearly all cases, the dietary intake of patients is significantly decreased [28][29][30]. This eating complication, in some cases, can lead to malnutrition, which explains why COVID-19 patients are one of the malnutrition high-risk populations during hospitalisation [28][29][31]. There is also evidence that even diet pattern is associated with a higher risk of COVID-19 hospitalisation [12].

Mechanism of Sarcopenia

The sarcopenia mechanism is simple and has a close mechanism with COVID-19. Generally increased inflammation that describes an increase in IL-6, IFNγ, TNFα, IL-2, and IL-1β is one of the most related factors to wasting [17]. On the other hand, estrogen levels, Myostatin and insulin-resistant are directly, and IGF-I, HGH, and Testosterone are negatively associated with sarcopenia [17]. Besides, malnutrition can lead to weight loss, muscle destruction, increased inflammation, and more severe conditions even without other pathways [30][32][33][34][35][36]. All these patterns that are directly or indirectly elevated during COVID-19 can result in wasting and sarcopenia.

The most interesting condition is related to Myostatin, which increases during this condition and elevates the sarcopenia process [27]. In addition, more dietary intake is required during hospitalisation due to an increase in total and basal energy expenditure for metabolic functions [30][37]. This increase in malnutrition puts the patients in an extra catabolic phase that severe the disease and elevates the sarcopenia process [17][30][37].

The other pathway that can result from malnutrition is removing nutrients anti-inflammatory, antioxidant protective effect on both muscle oxidation and inflammation that can also effectively increase muscle catabolism and inflammation [17]. Other risk factors of sarcopenia are unhealthy lifestyle, low physical activity, and depression that meet both during and after hospitalisation [4][5][38]. Based on this evidence, COVID-19 infection can provide a suitable condition for Sarcopenia growth.

HealthCare During Hospitalization

Medical and hormone therapy

The COVID-19 patients are not hospitalised until the emergency stages, generally categorised as severe pneumonia and respiratory distress syndrome [12][14]. During this phase, patients generally have a high inflammatory response or metabolic dysfunction [12][14]. To control inflammation and inflammatory cytokine storms, medical therapy is the first line of treatment and should start as soon as possible [22]. The other intervention can be hormonotherapy that reported to be helpful [23]. Nevertheless, most studies investigating the effect of hormonotherapy are ongoing[23]. However, medical therapy due to renal and hepatic pressure should be limited as soon as improvements in patients' clinical stages are made (Figure 3) [39][40]. Replacing alternative medical care is highly recommended[39][40].



Figure 3. the stage of developing sarcopenia risk factors and required interventions during- and post-hospitalisation COVID-19 patients to stop sarcopenia development stratified by stage of hospitalisation. During hospitalisation is shown in green, and post-hospitalisation in purple. Some interventions are suggested to continue even after full recovery for a period of time. Black: sarcopenia monitoring tools, blue: outcome of COVID-19 that elevate the risk of sarcopenia, salmon: required interventions. **Abv**: EN: Enteral Nutrition, DASS-21: Depression Anxiety Stress Scales -21, BDI-13: Beck Depression Inventory-13.

Sarcopenia Assessment

Sarcopenia assessment is better to be started even from the first day of hospitalisation. As using dual-energy X-ray absorptiometry (DEXA) or bioelectric impedance analyser (BIA) is not possible in most cases, it is suggested to consider wasting and malnutrition indicators as an important indicators of sarcopenia risk during hospitalisation [41]. To assess the risk of wasting, some criteria were provided in Table 1 that can be effective [36][41][42][43][44][45]. Monitoring tools nationally or centrally established in that region can also be useful [42][43][44][45]. However, SARC-F can be the easiest method for predicting sarcopenia in these patients [46]. Though, SARC-F is a verbal tool that may not be a practical tool in cases that

are not capable of answering the questions. In this condition, clinical assessments may be more useful. In addition, we suggested considering the presents of even one sign of wasting within individuals as the risk of sarcopenia.

Table 1. The clinical criteria for diagnosing the Sarcopenia high-risk COVID-19 patients during hospitalisation.

assessment	Consideration for Sarcopenia
SARC-F	Scored 11-20
Weight	loss of more than 10% of body weight in the last 3 months
	BMI <20.5 kg/m^2 as low risk and <18.5 kg/m^2 as high risk
mid-upper arm circumference (MUAC)	Decreases in circumference
	under 24.5 cm
Grip strength (most accurate)	<17 kg for women and <27 kg for men
Nutritional screening tools	
MST	Score ≥2
MNA	For short-form score 8-11 at risk and ≤7 high risk
	For long-form score 17-23.5 at-risk and less than 7 high risk
MUST	score 1 at risk and ≥2 high risk
NRS	Score ≥2
SNACK	score 2 at risk and ≥3 high risk
PG-SGA	scores ≥9, the higher score indicate a higher risk
Diagnosis	
Nutritional monitoring tools because of their concentration of hospital wasting could be used as a predictive sarcopenia assessment tool. The presence of any following criteria should be considered as the risk of sarcopenia and the interventions are better to start.	

Nutrition

During hospitalisation, the protein and energy requirements increase[41][43][47][48]. This is along with mild to severe malnutrition [43][47][48]. In this malnutrition, less energy and protein intake leads to wasting, more inflammation, and severity of the disease [32][33][34][35][36]. By referring to the important pathway of nutrition in critically ill patients, sarcopenia and inflammation, controlling the patient's nutritional status can be the most effective intervention to both prevent sarcopenia and increase the survival chance of patients.

As the first line of controlling malnutrition, the monitoring using available tools like malnutrition screening tool (MST), mini nutritional assessment (MNA), malnutrition universal screening tool (MUST), nutrition risk screening (NRS), or short nutritional assessment questionnaire (SNAQ) can be very useful in both indicate the risk of malnutrition and sarcopenia [42]. These tools can be used for sarcopenia too; because of their structures that concentrate on wasting criteria as part of the malnutrition assessment [42].

Despite the best setting being oral intake, using enteral feeding can be useful[41][47][49]. The intervention should be

started as soon as possible. Although we do not have a firm nutritional guideline for COVID-19, we can use the same nutritional therapy that we use for infectious diseases [41][47][49].

It is expected that in COVID-19 patients, the energy requirement during hospitalisation increases at least 10 to 30% and up to 100% [41][43][47][48]. In this condition, providing at least 25 to 30 kcal/kg body-weight/day according to the clinical stage and the level of inflammation is important [41][43][47][48]. However, the best criteria to set the energy goal is to control or stop the weight loss during the hospitalisation [42][43][47].

Protein plays a vital role in maintaining muscle and tissue. The target daily protein intake is better to be at least 1.2 g/kg body-weight of patients and increase up to 2 g/kg according to clinical stage and the speed of wasting [41][43][47][48][49]. By providing sufficient protein and energy intake, a decreased risk for malnutrition, mortality and sarcopenia can be expected.

Evidence shows that using an enriched formula with arginine (14 g/day), glutamine (14 g/day) and b-hydroxyb-methylbutyrate (3 g/day) can lead to more weight gain in muscle mass [41]. There is also evidence that dietary antioxidant elements that are partly received from a diet like vitamin A, vitamin C, vitamin E, beta-carotene, lycopene, lutein, and selenium can lower inflammation and muscle loss [50]. Other evidence suggests that using low Dietary Inflammatory Index (low-DII) formulas could lower the speed of sarcopenia development [51]. At the same time, an enteral formula based on low-DII is under development with antioxidant nutrients, minerals and vitamins enrichment which can be used in COVID-19 patients [52]. However, there is still no available data about its efficiency in critically ill patients[52]. Though enriching EN formulas with antioxidants and high-quality amino acids can be helpful.

Depression

Depression is one of the other risk factors that are not only independently associated with sarcopenia but also rises significantly during hospitalisation [38][53]. For controlling the hospital depression, evaluating patients using simple valid comprehensive tools like Depression Anxiety Stress Scales-21 (DASS-21) and Beck Depression Inventory-13 (BDI-13) is important [53]. During hospitalisation, giving more attention to patients to make them feel better and performing required psychological intervention is suggested [38][53]. However, despite the interventions for controlling depression looking simple, their impact can affect all aspects of the treatment. There is evidence that shows the importance of a good mood in the process of treatment [54].

Physical Activity

In addition to clinical and biochemicals, the bedrest lowers the physical activity to nearly none, which is one of the main risk factors for sarcopenia [4][5]. Previous studies have shown that a program of hospital-supervised physical training in patients with cystic fibrosis could be useful, but the work on this subject is little [55]. Encouraging patients to do some daily in-bed activities like bed exercises can be useful to at least lower the risk of hands and legs muscle wasting and elevate their spiritual wellness [55][56]. This exercise at least can lower the risk of hospital depression as previously, the relation between physical activity and depression was established [56].

HealthCare After Hospitalization

Even after COVID-19 hospital discharge with controlling the disease, the risk of sarcopenia is still. The main reasons are the acquired risk factors of sarcopenia that are illustrated in Figure 1. For this reason, it is highly suggested to continue sarcopenia assessments for months after hospitalisation using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) guideline (Table 2) [45]. In addition, some strategies are better to be considered even after the recovery.



Figure 1. the related factors that could elevate the post-COVID-19 hospitalisation sarcopenia risk and the muscle-fat interaction self-generator process of sarcopenia that could lead to severe condition of sarcopenia during the time.

Table 2: The clinical criteria for diagnosing the Sarcopenia in COVID-19 patients after hospitalisation using EWGSOP2 sarcopenia cut-off points.

assessment	Consideration for Sarcopenia	
	men	women
Screening		
SARC-F	Scored 11-20	
complementary tests		
low strength		
Grip strength	<27 kg	<16 kg
Chair stand	>15 s for five rises	
low muscle quantity		
ASM	<20 kg	<15 kg
ASM/height^2	<7.0 kg/m^2	<5.5 kg/m^2
low performance		
Gait speed	≤0.8 m/s	
Diagnosis		
Pre sarcopenia	Only low strength	
Sarcopenia	low strength and low muscle quantity	
Severe Sarcopenia	low strength, low muscle quantity and low performance	

Nutrition

Nutritional interventions are not as vital as the hospitalisation but still are one of the important risk factors for sarcopenia. There is evidence that some eating complications can continue from weeks to months after COVID-19 recovery and affect patients diet [19][28][29]. It is suggested that the required nutritional intervention be made as well as during hospitalisation [49]. An intervention like diet therapy or EN feeding can be made too. In this stage, providing at least 1 to 1.2 g/kg of protein and a positive energy balance can be useful [41][43][47][48][49]. However, due to the importance of nutritional consultation and the impact of a routine follow-up, nutritional monitoring of recovered COVID-19 patients is vital [18][19].

Physical Activity

The bedrest condition is less concerned, but COVID-19 drove the worldwide population into an inactive, sedentary lifestyle [20]. Different studies reported a significant decrease in recorded daily steps during quarantine from about 10000 to 1500 steps/day [20][57]. This inactiveness can impact insulin sensitivity, which is another associated mechanism of sarcopenia development, as much as low physical activity [20][57]. This is while COVID-19 patients still experience hospital fatigues as well as a sedentary lifestyle that can lead to more weight loss and severer sarcopenia [58].

Several studies suggest having sports activities can be significantly helpful in preventing or treatment of sarcopenia [3][4][59]. In this condition designing specific physical training for during quarantine to increase the daily physical activities of individuals are vital; however, to our knowledge, still no published study concentrates on this strategy.

Nevertheless, Liu et.al. showed that an intervention by a physical activity program featuring aerobic, strength, balance, and flexibility training could be useful for muscle improvement in a high sarcopenia risk population [60].

Depression

Depression is also the other sarcopenia risk factor that can continue after the hospitalisation and worsen during home quarantine isolation (Figure 3) [38][61][62]. In this case, continuing the depression monitoring and psychological interventions are suggested. In addition to this monitoring, the role of the family can be very effective in controlling the depression during the quarantine [63]. The medical team should involve the patients families in providing a relaxing, pleasurable environment.

Limitation and strengths

To our knowledge, this is the first review that considers and provides methods to control the risk of developing sarcopenia in both hospitalisation and post-hospitalisation in COVID-19 patients. The strengths of the current study are its comprehensive point of view. The main limitation is the exploration phase of COVID-19, which is still unclear. Nevertheless, controlling sarcopenia is vital because the world population is getting old.

Conclusion

Sarcopenia and COVID-19 have a close pathway that can cause severer diseases. Monitoring sarcopenia and required interventions are better be made in COVID-19 patients as soon as possible. These interventions can trigger medical therapy, nutrition, psychological health and physical activity. All the interventions are better to continue until the removal of sarcopenia risk even after hospitalisation; otherwise, high morbidity and disability will be expected in survived COVID-19 patients.

References

1. ^ *Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity. 2020;109:102433.*
2. a, b, c *Wu SY, Yau HS, Yu MY, Tsang HF, Chan LWC, Cho WCS, et al. The diagnostic methods in the COVID-19 pandemic, today and in the future. Expert review of molecular diagnostics. 2020;20(9):985-93.*
3. a, b, c, d, e, f, g *Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019.*
4. a, b, c, d, e, f, g, h, i *Dent E, Morley J, Cruz-Jentoft A, Arai H, Kritchevsky S, Guralnik J, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. The journal of nutrition, health & aging. 2018;22(10):1148-61.*
5. a, b, c, d, e *Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Writing Group for the European*

Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.

6. [a, b, c, d] *Hanna JS. Sarcopenia and critical illness: a deadly combination in the elderly. Journal of Parenteral and Enteral Nutrition. 2015;39(3):273-81.*
7. [a, b, c, d, e] *Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. Journal of anesthesia. 2016;30(5):884-90.*
8. [^] *Ubachs J, Ziemons J, Minis-Rutten IJ, Kruitwagen RF, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle. 2019;10(6):1165-74.*
9. [^] *Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G, et al. Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis. Annals of hepatology. 2017;16(1):107-14.*
10. [^] *Matsubara Y, Matsumoto T, Inoue K, Matsuda D, Yoshiga R, Yoshiya K, et al. Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia. Journal of vascular surgery. 2017;65(5):1390-7.*
11. [^] *Sousa A, Guerra RS, Fonseca I, Pichel F, Amaral T. Sarcopenia and length of hospital stay. European journal of clinical nutrition. 2016;70(5):595-601.*
12. [a, b, c, d, e, f] *Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. Brain, behavior, and immunity. 2020;87:184-7.*
13. [a, b, c, d, e, f] *Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2021;591(7848):92-8.*
14. [a, b, c, d, e, f, g] *Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv. 2020.*
15. [^] *Hernández-Galdamez DR, González-Block MÁ, Romo-Dueñas DK, Lima-Morales R, Hernández-Vicente IA, Lumbreras-Guzmán M, et al. Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Archives of medical research. 2020;51(7):683-9.*
16. [^] *Zhao Y, Zhang Y, Hao Q, Ge M, Dong B. Sarcopenia and hospital-related outcomes in the old people: a systematic review and meta-analysis. Aging clinical and experimental research. 2019;31(1):5-14.*
17. [a, b, c, d, e, f] *Zembroń-Łacny A, Dziubek W, Rogowski Ł, Skorupka E, Dąbrowska G. Sarcopenia: monitoring, molecular mechanisms, and physical intervention. Physiological research. 2014;63(6).*
18. [a, b] *Fedele D, De Francesco A, Riso S, Collo A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. Nutrition. 2021;81:111016.*
19. [a, b, c] *Mattioli AV, Sciomer S, Cocchi C, Maffei S, Gallina S. Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(9):1409-17.*
20. [a, b, c, d] *Moro T, Paoli A. When COVID-19 affects muscle: effects of quarantine in older adults. European journal of translational myology. 2020;30(2).*
21. [^] *Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. Inflammation resolution: a dual-*

pronged approach to averting cytokine storms in COVID-19? Cancer and Metastasis Reviews. 2020;39(2):337-40.

22. [a, b, c, d, e] *Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 2020;20(6):363-74.*
23. [a, b, c, d, e, f] *Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallome G, Boccardo F. Sex hormones and hormone therapy during COVID-19 pandemic: implications for patients with cancer. Cancers. 2020;12(8):2325.*
24. [a, b] *Frysak Z, Schovanek J, Iacobone M, Karasek D. Insulin-like Growth Factors in a clinical setting: Review of IGF-I. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):347-51.*
25. [a, b] *Elijah IE, Branski LK, Finnerty CC, Herndon DN. The GH/IGF-1 system in critical illness. Best Practice & Research Clinical Endocrinology & Metabolism. 2011;25(5):759-67.*
26. [a, b] *Wirtz TH, Loosen SH, Buendgens L, Kurt B, Abu Jhaisha SA, Hohlstein P, et al. Low Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients. Diagnostics. 2020;10(8):574.*
27. [a, b, c] *Peng LN, Lee WJ, Liu LK, Lin MH, Chen LK. Healthy community-living older men differ from women in associations between myostatin levels and skeletal muscle mass. Journal of cachexia, sarcopenia and muscle. 2018;9(4):635-42.*
28. [a, b, c, d, e] *Headey DD, Ruel MT. The COVID-19 nutrition crisis: What to expect and how to protect. IFPRI book chapters. 2020:38-41.*
29. [a, b, c, d] *Fernández-Aranda F, Casas M, Claes L, Bryan DC, Favaro A, Granero R, et al. COVID-19 and implications for eating disorders. European Eating Disorders Review. 2020;28(3):239.*
30. [a, b, c, d] *Rolfes SR, Pinna K, Whitney E. Understanding normal and clinical nutrition: Cengage learning; 2020.*
31. [^] *Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. European journal of clinical nutrition. 2020;74(6):871-5.*
32. [a, b] *Pirlich M, Schütz T, Norman K, Gastell S, Lübke HJ, Bischoff SC, et al. The German hospital malnutrition study. Clinical nutrition. 2006;25(4):563-72.*
33. [a, b] *Shadmand Foumani Moghadam MR, Dahakzade F, Shariatmadar Tehrani N, Molavi SF, Kavoosi F, Hosseini Z. The High Prevalence of Malnutrition in the Cancer Patients Admitted to Omid Hospital in Mashhad, Iran Based on the PG-SGA Questionnaire (2020). Journal of Nutrition, Fasting and Health. 2021;9(1):43-9.*
34. [a, b] *Butterworth CE, Blackburn GL. Hospital malnutrition. Nutrition Today. 1975;10(2):8-18.*
35. [a, b] *Mogensen KM, Horkan CM, Purtle SW, Moromizato T, Rawn JD, Robinson MK, et al. Malnutrition, critical illness survivors, and postdischarge outcomes: a cohort study. Journal of Parenteral and Enteral Nutrition. 2018;42(3):557-65.*
36. [a, b, c] *Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney international. 1999;55(5):1899-911.*
37. [a, b] *Gariballa S, Forster S. Energy expenditure of acutely ill hospitalised patients. Nutrition journal. 2006;5(1):1-5.*
38. [a, b, c, d] *Chang K-V, Hsu T-H, Wu W-T, Huang K-C, Han D-S. Is sarcopenia associated with depression? A systematic review and meta-analysis of observational studies. Age and ageing. 2017;46(5):738-46.*
39. [a, b] *Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney international. 1993;44(3):643-53.*
40. [a, b] *Fervenza FC, Hsu FW, Tsao T, Friedlaender MM, Rabkin R. Response to growth hormone therapy in experimental*

ischemic acute renal failure. Journal of Laboratory and Clinical Medicine. 1999;133(5):434-9.

41. [a, b, c, d, e, f, g, h, i, j] *Ockenga J, Grimble R, Jonkers-Schuitema C, Macallan D, Melchior J-C, Sauerwein H, et al. ESPEN Guidelines on Enteral Nutrition: Wasting in HIV and other chronic infectious diseases. Clinical Nutrition. 2006;25(2):319-29.*
42. [a, b, c, d, e] *Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler TR. Critical role of nutrition in improving quality of care: an interdisciplinary call to action to address adult hospital malnutrition. Journal of the Academy of Nutrition and Dietetics. 2013;113(9):1219-37.*
43. [a, b, c, d, e, f, g, h, i] *Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clinical nutrition. 2019;38(1):48-79.*
44. [a, b] *Thorup L, Hamann SA, Kallestrup P, Hjortdal VE, Tripathee A, Neupane D, et al. Mid-upper arm circumference as an indicator of underweight in adults: a cross-sectional study from Nepal. BMC Public Health. 2020;20(1):1187.*
45. [a, b, c] *Zhuang C-L, Shen X, Zou H-B, Dong Q-T, Cai H-Y, Chen X-L, et al. EWGSOP2 versus EWGSOP1 for sarcopenia to predict prognosis in patients with gastric cancer after radical gastrectomy: Analysis from a large-scale prospective study. Clinical Nutrition. 2019.*
46. [^] *Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. Journal of cachexia, sarcopenia and muscle. 2016;7(1):28-36.*
47. [a, b, c, d, e, f, g, h, i] *van Niekerk G, Meaker C, Engelbrecht A-M. Nutritional support in sepsis: when less may be more. Critical Care. 2020;24(1):1-6.*
48. [a, b, c, d, e, f] *Wang P-y, Li Y, Wang Q. Sarcopenia: An underlying treatment target during the COVID-19 pandemic. Nutrition. 2021;84:111104.*
49. [a, b, c, d, e] *Thibault R, Seguin P, Tamion F, Pichard C, Singer P. Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance. Critical Care. 2020;24(1):447.*
50. [^] *Sinha-Hikim I, Sinha-Hikim AP, Parveen M, Shen R, Goswami R, Tran P, et al. Long-Term Supplementation With a Cystine-Based Antioxidant Delays Loss of Muscle Mass in Aging. The Journals of Gerontology: Series A. 2013;68(7):749-59.*
51. [^] *Gojanovic M, Holloway-Kew KL, Hyde NK, Mohebbi M, Shivappa N, Hebert JR, et al. The Dietary Inflammatory Index Is Associated with Low Muscle Mass and Low Muscle Function in Older Australians. Nutrients. 2021;13(4):1166.*
52. [a, b] *Jandari S, Mosalmanzadeh N, Ranjbar G, Rezvani R, Yousefian S, Shadmand Foumani Moghadam MR, et al. The Effects of Low Dietary Inflammatory Index Formula on the Inflammatory and Metabolic Biomarkers of Patients with Multiple Traumas in Intensive Care Units: A Study Protocol for a Single-blind, Randomized, Controlled Trial. Journal of Nutrition, Fasting and Health. 2021;9(1):64-9.*
53. [a, b, c] *Hatch R, Young D, Barber V, Griffiths J, Harrison DA, Watkinson P. Anxiety, depression and post traumatic stress disorder after critical illness: a UK-wide prospective cohort study. Critical care. 2018;22(1):1-13.*
54. [^] *Costa D, Mendes A, Abreu W. Health and mood among HIV-positive outpatients attending an ART Clinic of a University Hospital. Journal of Clinical Nursing. 2016;25(21-22):3209-18.*
55. [a, b] *Turchetta A, Salerno T, Lucidi V, Libera F, Cutrera R, Bush A. Usefulness of a program of hospital-supervised physical training in patients with cystic fibrosis. Pediatric pulmonology. 2004;38(2):115-8.*

56. [a, b]*Dinas P, Koutedakis Y, Flouris A. Effects of exercise and physical activity on depression. Irish journal of medical science. 2011;180(2):319-25.*
57. [a, b]*Davies KAB, Sprung VS, Norman JA, Thompson A, Mitchell KL, Halford JC, et al. Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. Diabetologia. 2018;61(6):1282-94.*
58. [^]*Franz K, Otten L, Müller-Werdan U, Doehner W, Norman K. Severe Weight Loss and Its Association with Fatigue in Old Patients at Discharge from a Geriatric Hospital. Nutrients. 2019;11(10):2415.*
59. [^]*Beaudart C, Dawson A, Shaw S, Harvey NC, Kanis J, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International. 2017;28(6):1817-33.*
60. [^]*Liu CK, Leng X, Hsu F-C, Kritchevsky S, Ding J, Earnest C, et al. The impact of sarcopenia on a physical activity intervention: the Lifestyle Interventions and Independence for Elders Pilot Study (LIFE-P). The journal of nutrition, health & aging. 2014;18(1):59-64.*
61. [^]*Lei L, Huang X, Zhang S, Yang J, Yang L, Xu M. Comparison of prevalence and associated factors of anxiety and depression among people affected by versus people unaffected by quarantine during the COVID-19 epidemic in Southwestern China. Medical science monitor: international medical journal of experimental and clinical research. 2020;26:e924609-1.*
62. [^]*Benke C, Autenrieth LK, Asselmann E, Pané-Farré CA. Lockdown, quarantine measures, and social distancing: Associations with depression, anxiety and distress at the beginning of the COVID-19 pandemic among adults from Germany. Psychiatry research. 2020;293:113462.*
63. [^]*Keitner GI, Ryan CE, Miller IW, Kohn R, Bishop DS, Epstein NB. Role of the family in recovery and major depression. The American Journal of Psychiatry. 1995.*